Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jeffrey J. Sevigny"'
Autor:
Jeffrey J. Sevigny, Olga Uspenskaya-Cadoz, Patricia Sondergaard, Jenny Velaga, Erin Mahoney, Jamie Benoit, Mark Lowrey
Publikováno v:
Alzheimer's & Dementia. 16
Publikováno v:
Alzheimer's & Dementia. 14:1232-1233
Autor:
Yvonne Milewski, Karen Marder, Steven S. Chin, Jeffrey J. Sevigny, Mark W. Albers, Marc L. Gordon
Publikováno v:
Movement Disorders. 20:610-613
Complications from human immunodeficiency virus (HIV)/acquired immune deficiency syndrome are notorious for mimicking other neurological diseases. We describe a case of HIV encephalitis presenting with the classic clinical features of Huntington's Di
Autor:
Steven M. Albert, Daniel McClernon, Jeffrey J. Sevigny, Karen Marder, Leon G. Epstein, Michael P. McDermott, Ned Sacktor, G. Riggs, Katherine Conant, Karl Kieburtz, Ola A. Selnes, Donna Palumbo, Bruce A. Cohen, Giovanni Schifitto, Yaakov Stern, Justin C. McArthur
Publikováno v:
Neurology. 63:2084-2090
To evaluate whether baseline levels of plasma and CSF HIV RNA, tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinase-2 (MMP-2), or macrophage colony stimulating factor (M-CSF) are predictors of i
Publikováno v:
American journal of Alzheimer's disease and other dementias. 25(2)
We explored the association of Alzheimer’s disease (AD) Assessment Scale (ADAS-Cog) item scores with AD severity using cross-sectional and longitudinal data from the same study. Post hoc analyses were performed using placebo data from a 12-month tr
Autor:
Jeffrey J, Sevigny, Steven S M, Chin, Yvonne, Milewski, Mark W, Albers, Marc L, Gordon, Karen, Marder
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 20(5)
Complications from human immunodeficiency virus (HIV)/acquired immune deficiency syndrome are notorious for mimicking other neurological diseases. We describe a case of HIV encephalitis presenting with the classic clinical features of Huntington's Di
Autor:
Steven M. Albert, Karl Kieburtz, Karen Marder, Ned Sacktor, Katherine Conant, Justin C. McArthur, Donna Palumbo, Bruce A. Cohen, Garrett Riggs, Yaakov Stern, Leon G. Epstein, Giovanni Schifitto, Daniel McClernon, Ola A. Selnes, Jeffrey J. Sevigny, Michael P. McDermott
Publikováno v:
Archives of Neurology. 64:97
Several markers of immune activation have been identified as potential prognostic markers for human immunodeficiency virus (HIV)-associated morbidity and mortality, but the results from studies are conflicting.To evaluate whether neurocognitive statu
Autor:
Sevigny J; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA. sevigny_jeffrey@lilly.com., Uspenskaya O; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Heckman LD; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Wong LC; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Hatch DA; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Tewari A; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Vandenberghe R; Neurology Service, University Hospitals Leuven, Leuven, Belgium and Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium., Irwin DJ; Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA., Saracino D; Sorbonne Université, Paris Brain Institute - Institut du Cerveau, ICM, Inserm, CNRS UMR 7225 APHP - Hôpital Pitié-Salpêtrière, Paris, France., Le Ber I; Sorbonne Université, Paris Brain Institute - Institut du Cerveau, ICM, Inserm, CNRS UMR 7225 APHP - Hôpital Pitié-Salpêtrière, Paris, France., Ahmed R; Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Rohrer JD; Department of Neurodegenerative Disease, Dementia Research Center, UCL Queen Square Institute of Neurology, London, UK., Boxer AL; Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA., Boland S; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Sheehan P; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Brandes A; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Burstein SR; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Shykind BM; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Kamalakaran S; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Daniels CW; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., David Litwack E; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Mahoney E; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Velaga J; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., McNamara I; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Sondergaard P; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Sajjad SA; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Kobayashi YM; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Abeliovich A; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA., Hefti F; Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA.
Publikováno v:
Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1406-1415. Date of Electronic Publication: 2024 May 14.
Autor:
Abeliovich A; Prevail Therapeutics, A Wholly-Owned Subsidiary of Eli Lilly and Company, New York, NY, USA., Hefti F; Prevail Therapeutics, A Wholly-Owned Subsidiary of Eli Lilly and Company, New York, NY, USA., Sevigny J; Prevail Therapeutics, A Wholly-Owned Subsidiary of Eli Lilly and Company, New York, NY, USA.
Publikováno v:
Journal of Parkinson's disease [J Parkinsons Dis] 2021; Vol. 11 (s2), pp. S183-S188.
Autor:
Molinuevo JL; BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Universitat Pompeu Fabra, Barcelona, Spain.; Unidad de Alzheimer y otros trastornos cognitivos, Hospital Clinic-IDIBAPS, Barcelona, Spain., Ayton S; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia., Batrla R; Roche Centralised and Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland., Bednar MM; Neuroscience Therapeutic Area Unit, Takeda Development Centre Americas Ltd, Cambridge, MA, USA., Bittner T; Genentech, A Member of the Roche Group, Basel, Switzerland., Cummings J; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA., Fagan AM; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA., Hampel H; AXA Research Fund and Sorbonne University Chair, Paris, France.; Sorbonne University, GRC No 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.; Brain and Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France.; Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpêtrière Hospital, AP-HP, Paris, France., Mielke MM; Departments of Epidemiology and Neurology, Mayo Clinic, Rochester, MN, USA., Mikulskis A; Biomarkers, Biogen, Cambridge, MA, USA., O'Bryant S; Department of Pharmacology and Neuroscience; Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA., Scheltens P; Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands., Sevigny J; Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Shaw LM; Department of Pathology and Laboratory Medicine, and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA, USA., Soares HD; Clinical Development Neurology, AbbVie, North Chicago, IL, USA., Tong G; Lundbeck, Deerfield, IL, USA., Trojanowski JQ; Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Zetterberg H; Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden.; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, London, UK., Blennow K; Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. kaj.blennow@neuro.gu.se.; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden. kaj.blennow@neuro.gu.se.
Publikováno v:
Acta neuropathologica [Acta Neuropathol] 2018 Dec; Vol. 136 (6), pp. 821-853. Date of Electronic Publication: 2018 Nov 28.